Our science in action
Through our research, clinical trials and business development, we follow the science to make the greatest difference for patients, now and in the future.
Our scientists are revolutionizing how we discover and develop medicines and vaccines
We’re focused on innovating in oncology, vaccines, infectious diseases, cardio-metabolic disorders, immunology, neuroscience and ophthalmology to address unmet needs. With a science-led but portfolio-driven approach, we’re advancing one of the largest and most diverse pipelines in our history. We’re pushing scientific boundaries driven by our investments in new tools and technologies , collaborating across our global R&D network and executing with speed and rigor.
2024 by the numbers
Research and development
Every day our scientists, from all backgrounds and disciplines, work together to use the power of leading-edge science to save and improve lives.
- 23,500 employees driving our research activities
- $17.9B invested in R&D in 2024
- 1,400+ publications by our scientists
Clinical trials
Clinical trials help identify potential new treatments to improve people’s health and save lives. We’re grateful to the thousands of volunteers who participate in our clinical trials around the world — making our research possible.
- 100,000+ patients enrolled
- 21,000+ trial sites
- 50+ countries where we’re conducting trials
- 330+ late-stage trials
Business development and licensing
With a robust pipeline and portfolio fueled by both our own discoveries and external innovation, we know that collaborations are critical to advancing bold science.
- 5 new acquisitions to augment our pipeline
- 75+ significant business development deals to enhance our pipeline
Our pipeline
We’re dedicated to translating breakthrough research into life-changing medicines and vaccines.
Careers
Are you interested in a career in R&D? Join us to help address some of the world's most difficult challenges.
R&D locations
Our R&D starts with the capabilities and expertise at our facilities, but we're open to collaboration anywhere the science leads us.
